30 November 2015 - The approval of this first and only immunostimulatory antibody for multiple myeloma is based on data from the randomized, open-label, Phase 3, ELOQUENT-2 study, which demonstrated that the ERd regimen resulted in a 30% reduction in the risk of disease progression or death compared to Rd alone (HR 0.70 [95% CI: 0.57, 0.85; p = 0.0004]).

For more details, go to: http://news.bms.com/press-release/bristol-myers-squibb-and-abbvie-receive-fda-approval-empliciti-elotuzumab-treatment-pa